People with higher chances of heart attack and strokes are often advised by their doctors to reduce their cholesterol levels by adapting a healthy lifestyle and with the assistance of some common cholesterol reducing dugs.
These drugs, some of which include Crestor and Lipitor, are effective in significantly reducing the risks of heart attack and are readily available at an affordable price. However, there are some deus which are prescribed to the patients with high levels of cholesterol but the cost of some them are really high.
One such drug is Repatha, this cholesterol reducing drug was cleared by the United States Food and Drug Association in 2015. However, most of the patients who require the drug cannot afford it because it costs a whopping $ 14,523 every year. The price of the drug is so high that even most of the medical insurances do not wish to pay for it.
There have been recent reports of people claiming that the particular drug has not been proven to be very effective to the people who suffer from high levels of cholesterol. Therefore, in order to find out if the claims held some truth, a study was conducted to note the effects of this new drug sponsored by Amgen, the maker of Repatha.
The study, called FOURIER, aimed to check if the drug could reduce the risk of developing major adverse cardiovascular event (MACE), which could refer to a heart attack, a stroke or even a cardiovascular death.
In order to reach their findings, the researchers conducted the study on around 27,564 patients, out of which nearly 80 percent of them had suffered from a heart attack. Half of these patients were given optimal quantity of statins along with Repatha, and the other half were given a placebo.
There researchers after evaluation found out that the use of the drug reduced the he drug reduced average low-density lipoproteins (LDL) from 92 to 30. A quarter of the people on the new drug had LDL level 19, which meant that the drug proved to be effective.